This test is most useful if any of these apply to you.
A high result on this test is one of the few routine lab numbers that can point in two completely different directions at once: trouble draining bile from your liver, or something happening in your bones. Figuring out which one is the whole job, because the workup and the stakes are not the same.
Clinically, a high ALP often starts a bile-flow workup. But the same value climbs with Paget's disease of bone, a healing fracture, or fast bone turnover. And a persistently low result, which is easy to overlook, can be the clue to hypophosphatasia, an inherited bone and tooth condition that changes which osteoporosis drugs are safe.
Alkaline phosphatase is shortened to ALP. It is an enzyme attached to the outside of many cells. Its job is to remove phosphate groups from nearby molecules. More than 80% of the ALP activity measured in adult blood comes from two places: liver and bone. Smaller amounts can come from the intestine and, during pregnancy, the placenta.
In the liver, ALP rises when bile is not draining properly, because the cells lining the bile ducts make more of it and release it into the blood. In bone, ALP reflects osteoblast work. Osteoblasts are the cells that build new bone. So a high number means either a bile-flow problem or busy bone remodeling, and the test alone cannot tell you which.
When high ALP is coming from the liver, it points to cholestasis. That means bile is not flowing out of the liver the way it should. This is a different pattern from direct liver-cell injury, where ALT or AST usually rise first. GGT is the companion test that helps confirm the source. GGT usually rises with liver and bile-duct sources, and it does not rise from bone disease. If GGT is also high, the liver is the likely origin.
Primary biliary cholangitis shows why ALP matters. In this disease, the immune system slowly damages the small bile ducts. ALP is used to judge whether treatment is quieting the disease and to predict outcomes. In a large international follow-up study, people in the better ALP response group after a year had about 84% ten-year survival without a transplant, versus about 62% in the worse response group.
When the source is bone, a high ALP reflects how fast bone is being broken down and rebuilt. In women after menopause, elevated ALP is often explained by high bone turnover. Bone-specific ALP can help confirm that the signal is coming from bone rather than liver.
It is also the standard first blood-test screen for Paget's disease of bone, where remodeling runs out of control. In older adults, a high ALP with normal ALT and AST raised the odds of Paget's disease roughly elevenfold, though it caught only about 58 out of 100 cases. A normal result does not rule it out. A bone-specific ALP test can separate bone from liver when the source is unclear.
Most people treat a low ALP as nothing. Persistently low ALP is the signature lab clue for hypophosphatasia. In that condition, ALPL variants leave the body with too little working alkaline phosphatase, so bone and teeth may not mineralize normally. In one series of adults with unexplained low ALP, a large share carried an ALPL mutation.
This is where ALP breaks the usual rule that lower is safer. It is not a good-number-bad-number marker. A high value can flag obstruction or fast bone turnover. A low value can flag failure to make enough working enzyme. Both ends of the range mean something, and low results matter partly because missing them can lead to the wrong osteoporosis treatment.
Higher ALP tracks with cardiovascular trouble even when it stays inside the normal range. In a prospective Chinese cohort of 26,389 adults followed for about seven years, men in the highest ALP quarter had about 22% higher cardiovascular disease risk and about 43% higher stroke risk than men in the lowest quarter. Women showed a smaller cardiovascular signal, and the stroke result was less clear.
The stroke link shows up elsewhere too, including in people with high blood pressure, though the relationship is not a straight line and the picture in acute stroke is mixed. Read this as a risk signal, not proof of cause. ALP may be marking inflammation, kidney-mineral problems, bile or liver stress, or calcium building up in artery walls. That makes it worth noticing and weak on its own.
In people already diagnosed with cancer, a rising ALP can reflect liver involvement or high bone-forming activity in tumors and bone metastases. Higher ALP has been linked to worse survival in colorectal cancer with liver metastases. In osteosarcoma, it has been studied as a bone-tumor marker but misses too many cases to stand alone. It is far too nonspecific to diagnose cancer on its own.
Elevated ALP is also associated with higher mortality in type 2 diabetes, chronic kidney disease, and hemodialysis. Some dialysis analyses weaken after liver and inflammation markers are added. The theme repeats: useful as a flag, weak as a standalone answer.
Your own ALP is fairly steady from day to day. In healthy people, the within-person variation is only about 5%, so a genuine change over time tends to mean something. But people differ from each other a lot, with between-person variation near 25%, which is why your result matters most compared against your own past numbers rather than a population range.
Single changes still deserve caution. In one primary sclerosing cholangitis trial, ALP varied by a median of about 12% over 12 weeks and 20% over a year after the trial drug and placebo groups were pooled. Some people had spontaneous drops of more than 40%. So trend it, but don't treat every wiggle as a new disease.
Several things shift ALP without any liver or bone disease behind it. The biggest is who you are: children and teenagers run much higher because their bones are growing, and pregnancy raises it because the placenta adds its own supply. Results need age-, sex-, and pregnancy-appropriate context.
If your ALP is high and nothing obvious explains it, the first move is to sort liver from bone. Check GGT. If it is also high, the source is likely the liver and bile ducts, and the next steps are bilirubin, liver imaging such as an ultrasound, and, for suspected autoimmune bile duct disease, antimitochondrial antibodies, often with a hepatologist involved.
If GGT is normal, look to bone. A bone-specific ALP, plus calcium, phosphorus, vitamin D, kidney function, and parathyroid hormone, helps sort out Paget's disease, a mineral problem, or overactive bone turnover. If the value is persistently low, recheck it and review whether another illness or medication could explain it. If it stays unexplained, check hypophosphatasia-specific clues before starting bisphosphonates or denosumab.
Evidence-backed interventions that affect your ALP level
ALP is best interpreted alongside these tests.
ALP is included in these pre-built panels.